FSIP1 Binds HER2 Directly to Regulate Breast Cancer Growth and Invasiveness.

Tong Liu,Hao Zhang,Li Sun,Danyu Zhao,Peng Liu,Meisi Yan,Neeha Zaidi,Sudeh Izadmehr,Animesh Gupta,Wahid Abu-Amer,Minna Luo,Jie Yang,Xunyan Ou,Yining Wang,Xuefeng Bai,Yan Wang,Maria I New,Mone Zaidi,Tony Yuen,Caigang Liu
DOI: https://doi.org/10.1073/pnas.1621486114
2017-01-01
Abstract:Significance Fibrous sheath interacting protein 1 (FSIP1) has recently been identified as a prognostic marker for human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Its increased expression is importantly associated with poor outcomes. Here, we document that FSIP1 is a signaling partner to HER2, and that FSIP inhibition reduces cell growth and invasiveness in HER2-positive breast cancer cells. Considering its limited expression in normal tissues, FSIP1 may become a potentially druggable target for the therapy of HER2-positive breast cancers, and provide a new mechanism for improved therapeutic responses to current HER2 blockers, such as trastuzumab.
What problem does this paper attempt to address?